Halozyme Therapeutics Inc (HALO)

Financial leverage ratio

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Total assets US$ in thousands 1,733,270 1,892,660 1,810,440 1,699,450 1,841,510 1,864,540 1,781,390 1,162,250 1,104,430 1,185,420 1,025,860 966,582 579,924 524,029 526,997 492,353 565,874 370,356 417,830 429,109
Total stockholders’ equity US$ in thousands 83,808 249,181 151,033 65,850 169,798 96,991 293,171 260,256 196,953 281,674 119,746 67,595 151,047 98,988 105,577 58,042 91,765 245,353 260,052 260,047
Financial leverage ratio 20.68 7.60 11.99 25.81 10.85 19.22 6.08 4.47 5.61 4.21 8.57 14.30 3.84 5.29 4.99 8.48 6.17 1.51 1.61 1.65

December 31, 2023 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $1,733,270K ÷ $83,808K
= 20.68

The financial leverage ratio of Halozyme Therapeutics Inc. has shown significant fluctuations over the past eight quarters. This ratio measures the extent to which the company relies on debt financing rather than equity to fund its operations.

In Q4 2023, the financial leverage ratio was 20.68, indicating that the company had a higher level of debt relative to equity. This increase from the previous quarter suggests a potential increase in debt obligations relative to its equity base.

Comparing Q4 2022 and Q4 2023, there has been a substantial increase in the financial leverage ratio from 10.85 to 20.68, signifying an elevated reliance on debt to finance operations over this period.

Q2 2022 exhibited a relatively lower financial leverage ratio of 6.08, which indicates a more balanced mix of debt and equity in the company's capital structure. However, this ratio increased in subsequent quarters, peaking at 25.81 in Q1 2023, reflecting a heightened level of leverage at that point in time.

Overall, the fluctuating trend in the financial leverage ratio of Halozyme Therapeutics Inc. suggests varying levels of financial risk and the company's changing capital structure as it navigates different financing arrangements. Monitoring this ratio will be crucial to assess the company's ability to meet its debt obligations and sustain a healthy financial position.